Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach

BACKGROUND: Up to 30% of hemophilia A patients develop inhibitory antibodies against the infused factor VIII (FVIII). The development of a deimmunized FVIII is an unmet high medical need. Although improved recombinant FVIII (rFVIII) products evolved within the last years, the immunogenicity has not...

Descripción completa

Detalles Bibliográficos
Autores principales: Winterling, Karina, Martin, William D., De Groot, Anne S., Daufenbach, Jens, Kistner, Steffen, Schüttrumpf, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456792/
https://www.ncbi.nlm.nih.gov/pubmed/34060724
http://dx.doi.org/10.1111/jth.15413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456792/
https://www.ncbi.nlm.nih.gov/pubmed/34060724
http://dx.doi.org/10.1111/jth.15413

Ejemplares similares